Table 1 Demographic and clinical variables comparing control subjects with either all schizophrenia cases, or control subjects compared to both the low-inflammation and high-inflammation schizophrenia biotype groups, for the tissue homogenate analyses (mRNA and protein)

n

28

28

15

13

Age (years)

52.5 (22–67)

54.5 (26–67)

t₍₅₄₎ = − 0.27, p = 0.79

51.0 (30–64)

56.0 (26–67)

F_{(2, 53)} = − 1.24, p = 0.29

Sex (M,F)

19,9

19,9

X² = 0.000, p = 1.0

11,4

8,5

X² = 0.44, p = 0.80

pH

6.6 ± 0.26 (5.8–67.0)

6.5 ± 0.20 (6.14–6.88)

t₍₅₄₎ = 2.52 p = 0.01^**

6.5 ± 0.2 (6.14–6.88)

6.4 ± 0.2 (6.20–6.79)

F_{(2, 53)} = 3.12, p = 0.052

PMI (h)

31.6 ± 10.2 (15–50)

35.6 ± 17.7 (5–72)

t_(43.17) = − 1.03, p = 0.31

33.4 ± 14.7 (18–64)

38.2 ± 21.0 (5–72)

F_{(2, 53)} = − 0.86, p = 0.42

RIN

5.5 ± 1.1 (3.0–7.3)

5.6 ± 1.3 (3.2–8.3)

t₍₅₄₎ = − 0.15, p = 0.88

5.5 ± 1.2 (3.30–7.20)

5.7 ± 1.3 (3.20–8.30)

F_{(2, 53)} = − 0.07, p = 0.92

Age at illness onset (years)

–

22.5 ± 7.4 (15–46)

–

21.5 ± 7.1 (15–39)

23.7 ± 7.9 (16–46)

Duration of illness (years)

–

28.8 ± 12.7 (3.5–49)

–

26.4 ± 11.6 (3.5–43)

31.6 ± 13.9 (5–49)

t₍₂₆₎ = − 1.07, p = 0.29

Daily CPZ equivalent dose (mg)^a

736.4 ± 520.4 (200–2363)

483.5 ± 177.6 (200–800)

1040.1 ± 637.1 (250–2362)

t₍₂₀₎ = − 2.91, p = 0.01^**

Last recorded CPZ equivalent dose (mg)^b

–

597.5 ± 497.6 (20–1732)

–

361.5 ± 316.6 (20–1333)

869.9 ± 538.8 (100–1732)

t₍₂₆₎ = − 3.09, p = 0.01^**